level-one heading

Writers
Data Analysts
Consultants
Product Developers
Researchers
Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 125 /hr
Hire William S.
United States
USD 125 /hr

Biotech Consultant | IND Strategy, Biomarkers, Translational Research | Expert Guidance for Drug Development

Profile Summary
Subject Matter Expertise
Services
Writing Clinical Trial Documentation, Medical Writing, Technical Writing
Work Experience

Founder and Principal Consultant

BioTargeted Solutions LLC

March 2025 - Present

Senior Director, Cancer Biology

Omega Therapeutics, Inc

March 2023 - February 2025

Director, Cancer Biology

Omega Therapeutics, Inc.

May 2020 - March 2023

Clinical Research Scientist

Karyopharm Therapeutics (United States)

April 2020 - June 2020

Senior Director, Research

resTORbio

August 2019 - January 2020

Director, Research and Clinical Development

Karyopharm Therapeutics (United States)

July 2017 - August 2019

Associate Director, Biology

Karyopharm Therapeutics (United States)

January 2016 - July 2017

Senior Scientist, Biology

Karyopharm Therapeutics (United States)

December 2011 - January 2016

Scientist, Biology

Karyopharm Therapeutics (United States)

March 2011 - December 2011

Scientific Technician

Fox Chase Cancer Center

January 2001 - August 2005

Education

PhD in Cell Biology (Cell and Developmental Biology)

Harvard University

September 2005 - March 2011

BS with Distinction in Biology and Minor in Chemistry (Biology)

Pennsylvania State University

1996 - 2000

Certifications
  • Certification details not provided.
Publications
JOURNAL ARTICLE
William Senapedis, Kayleigh M. Gallagher, Elmer Figueroa, Jeremiah D. Farelli, Robert Lyng, J. Graeme Hodgson, Charles W. O’Donnell, Joseph V. Newman, Madison Pacaro, Stephen K. Siecinski, et al. (2024). Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models . Nature Communications.
Khan, H.Y., Nagasaka, M., Aboukameel, A., Alkhalili, O., Uddin, Md.H., Bannoura, S.F., Mzannar, Y., Azar, I., Beal, E.W., Tobon, M.E., et al.(2023). Anticancer Efficacy of KRAS<sup>G12C</sup>Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS<sup>G12C</sup>-Mutant Pancreatic and Lung Cancers . Molecular Cancer Therapeutics. 22. (12). p. 1422-1433.
Cornell, R.F., Baz, R., Richter, J.R., Rossi, A., Vogl, D.T., Chen, C., Shustik, C., Alvarez, M.J., Shen, Y., Unger, T.J., et al.(2022). A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma . American Journal of Hematology. 97. (2). p. E54-E58.
Khan, H.Y., Uddin, M.H., Balasubramanian, S.K., Sulaiman, N., Iqbal, M., Chaker, M., Aboukameel, A., Li, Y., Senapedis, W., Baloglu, E., et al.(2022). Pak4 and nampt as novel therapeutic targets in diffuse large b-cell lymphoma, follicular lymphoma, and mantle cell lymphoma . Cancers. 14. (1).
Mpilla, G.B., Uddin, Md.H., Al-Hallak, M.N., Aboukameel, A., Li, Y., Kim, S.H., Beydoun, R., Dyson, G., Baloglu, E., Senapedis, W.T., et al.(2021). PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus . Molecular Cancer Therapeutics. 20. (10). p. 1836-1845.
Abril-Rodriguez, G., Torrejon, D.Y., Liu, W., Zaretsky, J.M., Nowicki, T.S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M.J., et al.(2020). Erratum: Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy (Nature cancer (2020) 1 1 (46-58)) . Nature cancer. 1. (2). p. 264.
Abril-Rodriguez, G., Torrejon, D.Y., Liu, W., Zaretsky, J.M., Nowicki, T.S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M.J., et al.(2020). PAK4 inhibition improves PD-1 blockade immunotherapy . Nature Cancer. 1. (1). p. 46-58.
Trott, J.F., Abu Aboud, O., McLaughlin, B., Anderson, K.L., Modiano, J.F., Kim, K., Jen, K.-Y., Senapedis, W., Chang, H., Landesman, Y., et al.(2020). Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer . Kidney360. 1. (5). p. 376-388.
Fischer, M.A., Friedlander, S.Y., Arrate, M.P., Chang, H., Gorska, A.E., Fuller, L.D., Ramsey, H.E., Kashyap, T., Argueta, C., Debler, S., et al.(2020). Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies . Blood Advances. 4. (3). p. 586-598.
Li, N., Lopez, M.A., Linares, M., Kumar, S., Oliva, S., Martinez-Lopez, J., Xu, L., Xu, Y., Perini, T., Senapedis, W., et al.(2019). Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom <sup>€</sup> macroglobulinemia . Clinical Cancer Research. 25. (1). p. 369-377.
Sexton, R., Mahdi, Z., Chaudhury, R., Beydoun, R., Aboukameel, A., Khan, H.Y., Baloglu, E., Senapedis, W., Landesman, Y., Tesfaye, A., et al.(2019). Targeting nuclear exporter protein XPO1/CRM1 in gastric cancer . International Journal of Molecular Sciences. 20. (19).
Mpilla, G., Aboukameel, A., Muqbil, I., Kim, S., Beydoun, R., Philip, P.A., Mohammad, R.M., Kamgar, M., Shidham, V., Senapedis, W., et al.(2019). PAK4-NAMPT dual inhibition as a novel strategy for therapy resistant pancreatic neuroendocrine tumors . Cancers. 11. (12).
Mitchell, S.R., Larkin, K., Grieselhuber, N.R., Lai, T.-H., Cannon, M., Orwick, S., Sharma, P., Asemelash, Y., Zhang, P., Goettl, V.M., et al.(2019). Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia . Blood Advances. 3. (3). p. 242-255.
Mohammad, R.M., Li, Y., Muqbil, I., Aboukameel, A., Senapedis, W., Baloglu, E., Landesman, Y., Philip, P.A., Azmi, A.S.(2019). Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation . Small GTPases. 10. (5). p. 367-377.
Gandhi, U.H., Senapedis, W., Baloglu, E., Unger, T.J., Chari, A., Vogl, D., Cornell, R.F.(2018). Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma . Clinical Lymphoma, Myeloma and Leukemia. 18. (5). p. 335-345.
Aboukameel, A., Muqbil, I., Baloglu, E., Senapedis, W., Landesman, Y., Argueta, C., Kauffman, M., Chang, H., Kashyap, T., Shacham, S., et al.(2018). Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression . Oncotarget. 9. (82). p. 35327-35342.
Kashyap, T., Argueta, C., Unger, T., Klebanov, B., Debler, S., Senapedis, W., Crochiere, M.L., Lee, M.S., Kauffman, M., Shacham, S., et al.(2018). Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents . Oncotarget. 9. (56). p. 30773-30786.
Argueta, C., Kashyap, T., Klebanov, B., Unger, T.J., Guo, C., Harrington, S., Baloglu, E., Lee, M., Senapedis, W., Shacham, S., et al.(2018). Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death . Oncotarget. 9. (39). p. 25529-25544.
Neggers, J.E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al.(2018). Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes . Nature Communications. 9. (1).
Takao, S., Chien, W., Madan, V., Lin, D.-C., Ding, L.-W., Sun, Q.-Y., Mayakonda, A., Sudo, M., Xu, L., Chen, Y., et al.(2018). Targeting the vulnerability to NAD + depletion in B-cell acute lymphoblastic leukemia . Leukemia. 32. (3). p. 616-625.
Rane, C.K., Patel, M., Cai, L., Senapedis, W., Baloglu, E., Minden, A.(2018). Decrypting the PAK4 transcriptome profile in mammary tumor forming cells using Next Generation Sequencing . Genomics. 110. (4). p. 248-256.
Rane, C., Senapedis, W., Baloglu, E., Landesman, Y., Crochiere, M., Das-Gupta, S., Minden, A.(2017). A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth . Scientific Reports. 7.
Hwang, V.J., Zhou, X., Chen, X., Trott, J., Abu Aboud, O., Shim, K., Dionne, L.K., Chmiel, K.J., Senapedis, W., Baloglu, E., et al.(2017). Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease . Kidney International. 92. (4). p. 922-933.
Azmi, A.S., Li, Y., Muqbil, I., Aboukameel, A., Senapedis, W., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M.G., Philip, P.A., et al.(2017). Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration . Oncotarget. 8. (47). p. 82144-82155.
Fulciniti, M., Martinez-Lopez, J., Senapedis, W., Oliva, S., Bandi, R.L., Amodio, N., Xu, Y., Szalat, R., Gulla, A., Samur, M.K., et al.(2017). Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma . Blood. 129. (16). p. 2233-2245.
Etchin, J., Berezovskaya, A., Conway, A.S., Galinsky, I.A., Stone, R.M., Baloglu, E., Senapedis, W., Landesman, Y., Kauffman, M., Shacham, S., et al.(2017). KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells . Leukemia. 31. (1). p. 143-150.
Vercruysse, T., De Bie, J., Neggers, J.E., Jacquemyn, M., Vanstreels, E., Schmid-Burgk, J.L., Hornung, V., Baloglu, E., Landesman, Y., Senapedis, W., et al.(2017). The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia . Clinical Cancer Research. 23. (10). p. 2528-2541.
Aboukameel, A., Muqbil, I., Senapedis, W., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M., Philip, P.A., Mohammad, R.M., Azmi, A.S.(2017). Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and stemness in pancreatic ductal adenocarcinoma . Molecular Cancer Therapeutics. 16. (1). p. 76-87.
Jiang, Y.-Y., Lin, D.-C., Mayakonda, A., Hazawa, M., Ding, L.-W., Chien, W.-W., Xu, L., Chen, Y., Xiao, J.-F., Senapedis, W., et al.(2017). Targeting super-enhancer-Associated oncogenes in oesophageal squamous cell carcinoma . Gut. 66. (8). p. 1358-1368.
Muqbil, I., Aboukameel, A., Elloul, S., Carlson, R., Senapedis, W., Baloglu, E., Kauffman, M., Shacham, S., Bhutani, D., Zonder, J., et al.(2016). Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone . Cancer Letters. 383. (2). p. 309-317.
Kashyap, T., Argueta, C., Aboukameel, A., Unger, T.J., Klebanov, B., Mohammad, R.M., Muqbil, I., Azmi, A.S., Drolen, C., Senapedis, W., et al.(2016). Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death . Oncotarget. 7. (48). p. 78883-78895.
Aboud, O.A., Chen, C.-H., Senapedis, W., Baloglu, E., Argueta, C., Weiss, R.H.(2016). Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth . Molecular Cancer Therapeutics. 15. (9). p. 2119-2129.
Senapedis, W., Crochiere, M., Baloglu, E., Landesman, Y.(2016). Therapeutic potential of targeting PAK signaling . Anti-Cancer Agents in Medicinal Chemistry. 16. (1). p. 75-88.
Taylor-Kashton, C., Lichtensztejn, D., Baloglu, E., Senapedis, W., Shacham, S., Kauffman, M.G., Kotb, R., Mai, S.(2016). XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells . Journal of Cellular Physiology. 231. (12). p. 2711-2719.
Ferreiro-Neira, I., Torres, N.E., Liesenfeld, L.F., Chan, C.H.F., Penson, T., Landesman, Y., Senapedis, W., Shacham, S., Hong, T.S., Cusack, J.C.(2016). XPO1 inhibition enhances radiation response in preclinical models of rectal cancer . Clinical Cancer Research. 22. (7). p. 1663-1673.
Kim, J., McMillan, E., Kim, H.S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, A., Villalobos, P., Neggers, J.E., Mendiratta, S., Wei, S., et al.(2016). XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer . Nature. 538. (7623). p. 114-117.
Azmi, A.S., Muqbil, I., Wu, J., Aboukameel, A., Senapedis, W., Baloglu, E., Bollig-Fischer, A., Dyson, G., Kauffman, M., Landesman, Y., et al.(2015). Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition . Scientific Reports. 5.
Crochiere, M., Kashyap, T., Kalid, O., Shechter, S., Klebanov, B., Senapedis, W., Saint-Martin, J.-R., Landesman, Y.(2015). Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds . BMC Cancer. 15. (1).
Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M.Y., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M., Munshi, A.A., et al.(2014). CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications . Leukemia. 28. (1). p. 155-165.
Senapedis, W.T., Baloglu, E., Landesman, Y.(2014). Clinical translation of nuclear export inhibitors in cancer . Seminars in Cancer Biology. 27. p. 74-86.
Yang, J., Bill, M.A., Young, G.S., La Perle, K., Landesman, Y., Shacham, S., Kauffman, M., Senapedis, W., Kashyap, T., Saint-Martin, J.-R., et al.(2014). Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells . PLoS ONE. 9. (7).
Gravina, G.L., Senapedis, W., McCauley, D., Baloglu, E., Shacham, S., Festuccia, C.(2014). Nucleo-cytoplasmic transport as a therapeutic target of cancer . Journal of Hematology and Oncology. 7. (1).
Salas Fragomeni, R.A., Chung, H.W., Landesman, Y., Senapedis, W., Saint-Martin, J.-R., Tsao, H., Flaherty, K.T., Shacham, S., Kauffman, M., Cusack, J.C.(2013). CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma . Molecular Cancer Therapeutics. 12. (7). p. 1171-1179.
Senapedis, W.T., Kennedy, C.J., Boyle, P.M., Silver, P.A.(2011). Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain . Molecular Biology of the Cell. 22. (10). p. 1791-1805.
G&#243;mez-Bald&#243;, L., Schmidt, S., Maxwell, C.A., Bonifaci, N., Gabald&#243;n, T., Vidalain, P.-O., Senapedis, W., Kletke, A., Rosing, M., Barnekow, A., et al.(2010). TACC3-TSC2 maintains nuclear envelope structure and controls cell division . Cell Cycle. 9. (6). p. 1143-1155.
Aldaye, F.A., Senapedis, W.T., Silver, P.A., Way, J.C.(2010). A structurally tunable DNA-based extracellular matrix . Journal of the American Chemical Society. 132. (42). p. 14727-14729.
Astrinidis, A., Senapedis, W., Henske, E.P.(2006). Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner . Human Molecular Genetics. 15. (2). p. 287-297.
Astrinidis, A., Senapedis, W., Coleman, T.R., Henske, E.P.(2003). Cell Cycle-regulated Phosphorylation of Hamartin, the Product of the Tuberous Sclerosis Complex 1 Gene, by Cyclin-dependent Kinase 1/Cyclin B . Journal of Biological Chemistry. 278. (51). p. 51372-51379.
Khare, L., Astrinidis, A., Senapedis, W., Adams, P.D., Henske, E.P.(2002). Expression of wild type and mutant TSC2, but not TSC1, causes an increase in the G1 fraction of the cell cycle in HEK293 cells . Journal of Medical Genetics. 39. (9). p. 676-680.
OTHER
Khan, H.Y., Nagasaka, M., Aboukameel, A., Alkhalili, O., Uddin, Md.H., Bannoura, S., Mzannar, Y., Azar, I., Beal, E., Tobon, M., et al.(2023). Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers . bioRxiv.